Learn about the flu shot, COVID-19 vaccine, and our masking policy »
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Get the iPhone MyHealth app »
Get the Android MyHealth app »
Abstract
Carcinoid tumors have high numbers of somatostatin receptors that allow scintigraphic imaging with the radiolabeled somatostatin analog octreotide. Experience, however, with PET using 2-[18F]fluoro-2-deoxy-D-glucose (18FDG) in carcinoid is very limited. In two prior studies which investigated the utility of 18FDG-PET in cancer detection, three patients with small, solitary, indolent carcinoid tumors had false-negative results. We report a case where 18FDG-PET imaging was false-negative in a patient with known metastatic carcinoid and a positive octreotide scan.
View details for Web of Science ID A1997XV76600020
View details for PubMedID 9293792